The Japanese drugmaker said that interim results from the 530-patient VISIONARY study showed that sibeprenlimab achieved a ...

To learn more about the true value of AI and GenAI, pharmaphorum spoke with Sudip Chakraborty, Principal and Head of AI/GenAI ...

In 2018, the EEA accounted for 18% and China made up around 9%, with the massive increase in the latter in a few short years ...

AstraZeneca and Ionis are set fair for EU approval of Wainzua, their treatment for polyneuropathy associated with ...

Earlier this month, Sanofi revealed talks were ongoing with CD&R, and has now confirmed the negotiations could result in the ...

Boston-based Seaport said the money would support a pipeline of improved neuropsychiatric drug candidates led by SPT-300, an ...

The increasing complexity of emerging therapies and the need for faster development have led to the adoption of advanced ...

Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...

Novo Nordisk's anti-TFPI antibody concizumab has been backed for approval in the EU as a once-daily drug to prevent bleeding ...

Following the discussion, attendees will have the opportunity to participate in a live Q&A session, further addressing ...

Vyloy is the first CLDN18.2-targeting drug to reach the US market but has already been approved in Japan as well as in the EU ...